Tiny biotech Mapp's Ebola drug thrust into spotlight

An experimental treatment used in at least two American aid workers infected with the deadly Ebola virus may have helped improve those patients' conditions – thrusting the tiny US biotech that is developing the drug, which has not yet been tested in human clinical trials, into the spotlight.